Long-term real-world thrombotic and clinical outcomes in polycythemia vera - a hospital-based i2b2 cohort study

真性红细胞增多症患者的长期真实世界血栓形成和临床结局——一项基于医院的i2b2队列研究

阅读:2

Abstract

Though the thrombotic risk in polycythemia vera (PV) is well known, long-term real-world data remain limited. This retrospective study at Bern University Hospital aimed to evaluate complications in PV patients, focusing on thrombotic events, associated risk factors, and disease outcomes. Among 727,731 screened adults, 107 PV patients were identified (median age 58 years, range 18–92; 51% male). Median follow-up was 115 months (range 1–353). Thrombotic events occurred in 56% of patients, including 58% arterial and 42% venous events. Arterial and venous thrombosis before or at diagnosis was documented in 9 (8.4%) and 36 (33.6%) patients, respectively, and in 13 (12.1%) during follow-up. Splanchnic thrombosis was associated with younger age and splenomegaly. Multivariate analysis showed an increased thrombotic risk linked to dyslipidemia (RR 2.573, 95% CI 1.058–6.257) and older age at diagnosis (> 60 years; RR 2.524, 95% CI 1.111–5.734). Risk of death increased with age (RR 1.052, 95% CI 1.009–1.097) and myelofibrosis transformation (RR 6.856, 95% CI 1.948–24.120). This long-term study confirms a high thrombotic burden in PV, especially arterial events. Splanchnic thrombosis typically presented early on in younger patients without recurrence. The high prevalence of cardiovascular risk factors highlights the critical importance of managing these risks to mitigate thrombotic complications in PV. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00277-026-06768-w.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。